Vascular endothelial growth factor, tissue factor, coagulation and fibrinolysis markers in slow-flow vascular malformations: a prospective study of treatment with sirolimus

Br J Dermatol. 2023 Jan 23;188(1):152-154. doi: 10.1093/bjd/ljac028.

Affiliations

¹ University of Tours, University of Nantes, INSERM, SPHERE U1246, Tours, France.
² CHRU Tours, Department of Dermatology, Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC-Tours), Tours, France.
³ University of Tours, CHRU Tours, Department of Hemostasis, Tours, France.

PMID: 36689523
DOI: 10.1093/bjd/ljac028

No abstract available

MeSH terms

Fibrinolysis*
Humans
Prospective Studies
Sirolimus
Thromboplastin
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Vascular Malformations*

Substances

Sirolimus
Vascular Endothelial Growth Factor A
Thromboplastin
Vascular Endothelial Growth Factors